Fundraising Fox

Innovate Biopharmaceuticals

Raleigh, US · Founded 2014 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

KW
Kendyle WoodardExecutive
MR
Michael RiddlingExecutive
JT
Jawahar TandonExecutive
JM
Jay MadanNamed on SEC filing
SL
Sandeep LaumasNamed on SEC filing
CP
Christopher P. PriorNamed on SEC filing

Board

SR
Saira RamasastryBoard director
RP
Roy ProujanskyBoard director
AM
Anthony MaidaBoard director
LJ
Lorin JohnsonBoard director
VT
Vivek TandonBoard director
DT
Devinder TandonBoard director

Investors · 1

OrbiMedreportedNew York · $1M – $75M

Reported raises · per SEC filings

Form D private placements

$191.3M disclosed across 16 rounds · 2014–2020

▶$22.6MraisedMay 2020 · 149 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy ProujanskyDirector
  • Edward J. SitarExecutive Officer
  • Sandeep LaumasDirector
  • Lorin K. JohnsonDirector
  • Nissim DarvishDirector
  • Mark SirgoDirector
  • John TemperatoExecutive Officer, Director
Offering amount
$22.6M
Amount sold
$22.6M
Sales commissions
$2.1M
Placement agents
Wynston Hill Capital, Westpark Capital, Inc., GP Numenkari Inc., National Securities Corporation, William Blair & Company, LLC.
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJan 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sandeep LaumasExecutive Officer, Director
  • Jay MadanExecutive Officer, Director
  • Anthony MaidaDirector
  • Edward J SitarExecutive Officer
  • Saira RamasastryDirector
  • Roy ProujanskyDirector
  • Lorin JohnsonDirector
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$487.1KraisedMay 2019 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay P MadanExecutive Officer, Director
  • Sandeep LaumasExecutive Officer, Director
  • Lorin K JohnsonDirector
  • Saira RamasastryDirector
  • Roy ProujanskyDirector
  • Anthony E Maida IIIDirector
Offering amount
$487.1K
Amount sold
$487.1K
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.7MraisedMay 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sandeep LaumasExecutive Officer, Director
  • Jay MadanExecutive Officer, Director
  • Roy ProujanskyDirector
  • Lorin JohnsonDirector
  • Saira RamasastryDirector
  • Anthony MaidaDirector
Offering amount
$8.7M
Amount sold
$8.7M
Sales commissions
$612.1K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.7MraisedApr 2019 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Saira RamasastryDirector
  • Roy ProujanskyDirector
  • Anthony MaidaDirector
  • Jay MadanExecutive Officer, Director
  • Sandeep LaumasExecutive Officer, Director
  • Lorin JohnsonDirector
Offering amount
$9.7M
Amount sold
$9.7M
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedMar 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy ProujanskyDirector
  • Jay MadanExecutive Officer, Director
  • Lorin JohnsonDirector
  • Sandeep LaumasExecutive Officer, Director
  • Anthony MaidaDirector
  • Saira RamasastryDirector
Offering amount
$5.5M
Amount sold
$5.5M
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedOct 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Saira RamasastryDirector
  • Roy ProujanskyDirector
  • Anthony MaidaDirector
  • Christopher PriorExecutive Officer, Director
  • Lorin JohnsonDirector
  • Jay MadanExecutive Officer, Director
  • Sandeep LaumasExecutive Officer, Director
Offering amount
$5.2M
Amount sold
$5.2M
First sale
Oct 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedFeb 2018 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay MadanExecutive Officer, Director
  • Sandeep LaumasExecutive Officer, Director
  • Christopher PriorExecutive Officer
Offering amount
$4.8M
Amount sold
$4.8M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD Pharmafinance.yahoo.com · Apr 2020Innovate down 20% on capital raise dilution (NASDAQ:INNT) | Seeking Alphaseekingalpha.com · Apr 2019Buy Innovate Biopharmaceuticals Stock – INNT Stock Quote Today & Investment Insights - Public.compublic.com · Apr 2019Innovate Biopharmaceuticals raises another $9.7 million in search for more capital - Triangle Business Journalbizjournals.com · Mar 2019How Financially Strong Is Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? - Simply Wall St Newssimplywall.st · Jun 2018Is Innovate Biopharmaceuticals Inc’s (NASDAQ:INNT) Balance Sheet Strong Enough To Weather A Storm?finance.yahoo.com · Jun 2018

Frequently asked questions

Who are Innovate Biopharmaceuticals's investors?
Innovate Biopharmaceuticals's investors include OrbiMed.
How much funding has Innovate Biopharmaceuticals raised?
Innovate Biopharmaceuticals has disclosed $191.3M raised across 16 rounds.
Where is Innovate Biopharmaceuticals headquartered?
Innovate Biopharmaceuticals is headquartered in Raleigh, US.